课题基金 / 基金详情

Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials

Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials
研究 microRNA-146a 活性调节生物材料异物反应的机制
批准号:
10522163
负责人:
Xiaoming He
金额:
$73.69万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-10 至 2027-05-31

项目摘要

项目成果

Xiaoming He的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Implantation of biomaterials and devices often leads to the development of a foreign body response (FBR), a chronic inflammatory condition that can ultimately lead to implant failure, which may cause harm to or death of the patient. The molecular mechanisms underlying the FBR remain poorly understood. Improved understanding of the molecular mechanisms underlying the generation of FBR is the most important step for the development of novel and effective therapeutic strategies that eliminate or reduce the FBR. Macrophages are central to development and progression of the FBR. They participate in the expression of inflammatory proteins, formation of destructive foreign body giant cells (FBGCs), remodeling of the extracellular matrix, and encapsulation of the implant. Emerging data support a critical role for a mechanical signal, e.g., matrix stiffness, in macrophage activation. MicroRNAs (miRs) are endogenous, small, non-coding RNAs that have emerged as powerful regulators of gene expression in numerous cellular processes including macrophage activation, cell fusion, inflammation, and fibrosis. The function of specific miRs in regulation of FBR to biomaterials is uncertain; specifically, it remains an open question whether matrix stiffness regulates miR expression to drive FBR. These gaps pose a significant barrier to progress in the FBR field. In recent, exciting preliminary data, we obtained evidence that miR-146a may be a negative regulator of FBR to biomaterials. Specifically, we found that: 1) miR-146a expression levels decreased in the implant-adhered tissues in a subcutaneous (s.c) implantation model, which correlated with increased macrophage accumulation, FBGC formation, and collagen accumulation; 2) miR-146a deletion in mice exacerbated FBR processes in a s.c implantation model; 3) the severity of the in vivo macrophage accumulation at the tissue-implant interface was dependent on the stiffness of the implant; 4) genetic ablation of miR-146a augmented macrophage adhesion and spreading on stiff matrix, FBGC formation, and inflammation in macrophages, and 5) genetic ablation of TRPV4, an ion channel in the transient receptor potential vanilloid family, inhibited development of implant-adhered tissue stiffness under FBR as determined by Atomic Force Microscopy. Further preliminary data suggested an association between matrix stiffness, miR-146a activity, and TRPV4, under FBR conditions. The objective of this proposal is to define the role of miR-146a in the FBR, and to elucidate the underlying molecular mechanisms. Based on our preliminary data, our central hypothesis is that miR-146a modulates the FBR to biomaterials by regulating macrophage activation and fibrogenesis in a manner dependent on implant-induced change in tissue stiffness. We will test our hypothesis through molecular gain- or loss-of-function studies. We expect that the results of this study may provide invaluable information and insight regarding the molecular mechanisms mediating the FBR to biomaterials, which may lead to the development of a novel and effective microRNA-based therapeutic strategy for the amelioration of the poorly understood FBR to biomaterials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multiscale hydrogel biomaterials-enabled 3D modeling of cancer drug resistance
  • 批准号:
    10639167
  • 项目类别:
  • 资助金额:
    $44.03万
  • 财政年份:
    2023
  • 负责人:
    Xiaoming He
  • 依托单位:
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
  • 批准号:
    10593921
  • 项目类别:
  • 资助金额:
    $44.19万
  • 财政年份:
    2020
  • 负责人:
    Xiaoming He
  • 依托单位:
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
  • 批准号:
    10376777
  • 项目类别:
  • 资助金额:
    $44.16万
  • 财政年份:
    2020
  • 负责人:
    Xiaoming He
  • 依托单位:
Nanotechnology enabled targeting of p53 deficiency in human cancer
  • 批准号:
    10063652
  • 项目类别:
  • 资助金额:
    $4.28万
  • 财政年份:
    2018
  • 负责人:
    Xiaoming He
  • 依托单位:
海外基金